CIK 0001766140 · <br>Emerging growth company
Unicycive Therapeutics, Inc.
Sign in to watch- Ticker
- UNCY
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 813638692
- Phone
- 650-384-0642
- Business address
- 1975 W. EL CAMINO REAL, SUITE 204, MOUNTAIN VIEW, CA, 94040
- Former names
- Unicycive Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-11 | Gupta Pramod EVP, Pharmaceuticals and BD | Option exercise | +41,845 | 41,845 | ||
| 2023-07-11 | Gupta Pramod EVP, Pharmaceuticals and BD | Option exercise · Series A-1 Convertible Preferred Stock | −20 | $1,000.00 | $20K | 0 |
| 2023-07-11 | Gupta Pramod EVP, Pharmaceuticals and BD | Option exercise · Warrant (right to buy | +31,700 | 31,700 | ||
| 2023-07-11 | Gupta Pramod EVP, Pharmaceuticals and BD | Option exercise · Warrant (right to buy) | +28,818 | 28,818 | ||
| 2023-07-11 | Gupta Pramod EVP, Pharmaceuticals and BD | Option exercise · Warrant (right to buy) | +46,110 | 46,110 | ||
| 2023-07-11 | Gupta Shalabh K. CEO | Option exercise | +104,612 | 2,527,449 | ||
| 2023-07-11 | Gupta Shalabh K. CEO | Option exercise · Series A-1 Convertible Preferred Stock | −50 | $1,000.00 | $50K | 0 |
| 2023-07-11 | Gupta Shalabh K. CEO | Option exercise · Warrant (right to buy | +79,252 | 79,252 | ||
| 2023-07-11 | Gupta Shalabh K. CEO | Option exercise · Warrant (right to buy) | +72,047 | 72,047 | ||
| 2023-07-11 | Gupta Shalabh K. CEO | Option exercise · Warrant (right to buy) | +115,275 | 115,275 | ||
| 2023-03-08 | Aggarwal Gaurav Director | Grant or award · Series A-1 Convertible Preferred Stock | +8,077 | $1,000.00 | $8.1M | 8,077 |
| 2023-03-08 | Gupta Shalabh K. CEO | Grant or award · Series A Convertible Preferred Stock | +50 | $1,000.00 | $50K | 50 |
| 2023-03-08 | Gupta Pramod EVP, Pharmaceuticals and BD | Grant or award · Series A Convertible Preferred Stock | +20 | $1,000.00 | $20K | 20 |
| 2023-03-08 | Jermasek Douglas EVP of Corporate Strategy | Grant or award · Series A Convertible Preferred Stock | +50 | $1,000.00 | $50K | 50 |
| 2022-11-21 | Gupta Pramod EVP, Pharmaceuticals and BD | Grant or award · Stock Options | +28,000 | 219,862 | ||
| 2022-11-21 | Townsend John Chief Financial Officer | Grant or award · Stock Options | +35,000 | 76,861 | ||
| 2022-11-21 | Jermasek Douglas EVP of Corporate Strategy | Grant or award · Stock Options | +55,000 | 155,000 | ||
| 2022-11-21 | Gupta Shalabh K. CEO | Grant or award · Stock Options | +86,000 | 202,279 | ||
| 2022-07-15 | Schiller Brigitte Director | Option exercise | +26,738 | 26,738 | ||
| 2022-07-15 | Schiller Brigitte Director | Option exercise · Restricted Stock Units | −26,738 | 0 |
Page 4 of 5 · 84 trades